Biotech Archives - Page 53 of 795

2 minute read

Pasithea Therapeutics Announces PAS-004 Abstract Accepted For Poster Presentation At 2024 ASCO Annual Meeting

April 29, 8:14 AM

Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type

KTTA

2 minute read

NKGen Biotech Announces FDA Clearance Of IND Application For SNK01 NK Cell Therapy in Parkinson’s Disease

By Benzinga Newsdesk

April 29, 8:08 AM

NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson's disease. The Company expects to initiate a Phase 1 clinical trial in

NKGN

2 minute read

“LGBTQ Health Care Bias Protections Gets HHS Green Light; Health Programs Can’t Discriminate Against LGBTQ Patients” – Bloomberg Law

By Benzinga Newsdesk

April 26, 4:47 PM

https://news.bloomberglaw.com/daily-labor-report/lgbtq-health-care-bias-protections-gets-hhs-greenlightHealth programs can't discriminate against LGBTQ patientsRule follows US Supreme Court decision in BostockThe Biden

SPY

2 minute read

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle

By Vandana Singh

April 26, 2:45 PM

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent infringement in mRNA technology.

BNTX

2 minute read

FDA Green Lights Pfizer’s Gene Therapy For Rare Bleeding Disorder Hemophilia

By Vandana Singh

April 26, 2:30 PM

FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.

CSLLY

2 minute read

Ex-Humira Growth Platform Drives AbbVie’s Q1 Performance, Drugmaker Lifts Annual Profit Outlook

By Vandana Singh

April 26, 9:54 AM

AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains.

ABBV

1 minute read

Amgen Seeks EMA Approval For Teprotumumab In Moderate To Severe Thyroid Eye Disease

By Benzinga Newsdesk

April 26, 9:02 AM

Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted

AMGN

3 minute read

Biodexa Enters Into Exclusive License To eRapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP

By Benzinga Newsdesk

April 26, 8:34 AM

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)Worldwide rights come with $17

BDRX

2 minute read

Takeda Receives Positive CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer

By Benzinga Newsdesk

April 26, 8:32 AM

− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade− Positive Opinion Based on Results from a Phase

TAK

2 minute read

Sobi Receives Positive CHMP Opinion Recommending Approval Of Efanesoctocog Alfa For Once-Weekly Treatment Of Haemophilia A

By Benzinga Newsdesk

April 26, 8:06 AM

Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and

SNY